Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | GALR2 | O43603 | 1/20 | 0.34 |
| ▸ | GALR1 | P47211 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25620238 | 1.00 | JAK3 (0.37) | JAK3RBP4GPR119RETSMARCA2 | |
| SCHEMBL25621191 | 0.93 | GPR119 (0.37) | JAK3GPR119RETSMARCA2SMARCA4 | |
| SCHEMBL25864592 | 0.90 | JAK3 (0.36) | JAK3RBP4RETCKS1BSKP1 | |
| SCHEMBL25864343 | 0.87 | CKS1B (0.41) | JAK3RBP4RETCKS1BSKP1 | |
| SCHEMBL25620162 | 0.86 | GPR119 (0.45) | JAK3GPR119RET | |
| SCHEMBL25620790 | 0.83 | RBP4 (0.48) | RBP4GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL25859958 | 0.81 | ABCB1 (0.32) | JAK3GPR119RETABCB1PIK3R1 | |
| SCHEMBL25859999 | 0.80 | ABCB1 (0.31) | GPR119RETABCB1 | |
| SCHEMBL25650214 | 0.77 | GPR119 (0.47) | GPR119SMARCA2SMARCA4PBRM1ABCB1 | |
| SCHEMBL25650213 | 0.74 | HRH3 (0.43) | GPR119SMARCA2SMARCA4PBRM1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | JAK3 121/4885RBP4 3238/4885GPR119 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.